Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
October 29, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day
October 22, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
Company’s Chief Scientific Officer to Participate in “New Approaches to Combating Opioids” Panel SANTA MONICA, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant")...
Opiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin Vaccine
October 18, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 28, 2018 16:01 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
Opiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference
September 26, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock
September 25, 2018 09:26 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 24, 2018 16:01 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
September 20, 2018 16:05 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug...
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
September 10, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing...
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
September 04, 2018 08:00 ET
|
Opiant Pharmaceuticals, Inc.
Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical...